RESEARCH TRIANGLE PARK, N.C., July 15, 2026 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) (“BioCryst” or the “Company”) today announced the appointment of David W. Jenkins, MA, PhD, to the newly created position of Chief Scientific Officer, effective immediately, reporting to Dr. Sandeep Menon, Chief Research and Development Officer. In this role, Dr. Jenkins will build and lead an efficient research team focused on leveraging external innovation, capabilities and partnerships to accelerate the delivery of transformative rare disease therapies to patients. He will be based in the Company’s Boston office. Dr. Jenkins has spent over 20 years working in the biopharmaceutical industry and brings broad experience leading R&D and external innovation programs across a range of therapeutic areas, development stages...

MARKHAM, Ontario, July 15, 2026 (GLOBE NEWSWIRE) — Pet Valu Holdings Ltd. (“Pet Valu” or the “Company”) (TSX: PET), the leading Canadian specialty retailer of pet food and pet-related supplies, will release its financial results for the second quarter of fiscal 2026 on Tuesday, August 11, 2026 at approximately 6:30am ET, followed by a live webcast and conference call at 8:30am ET. The live webcast can be accessed through the Events & Presentations section of the Company’s website at investors.petvalu.ca. Participants can also dial-in to the conference call by pre-registering using this link. Registrants will receive an email, including dial-in details and a unique access code required to join the live call. Please ensure you have registered at least 15 minutes prior to the conference call time. For those unable to attend,...

FDA sets PDUFA target action date of May 1, 2027 NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s New Drug Application (NDA) for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027. The FDA also indicated that it does not currently plan to hold an advisory committee meeting to discuss the application. About Narcolepsy Narcolepsy is a serious and debilitating orphan neurological condition that causes dysregulation of the sleep-wake cycle and is characterized clinically by excessive daytime...

Chicago-born brand celebrates National Hot Dog Day by announcing plans to open its newest restaurant in the Wrigleyville neighborhood and inviting Chicagoland fans to a special Hot Dog Season pop-up celebration, just steps from the ballpark OAK BROOK, Ill., July 15, 2026 (GLOBE NEWSWIRE) — On the holiday that celebrates the food that made it famous, Portillo’s (NASDAQ: PTLO) today announced it will open a new restaurant location in the heart of Wrigleyville, further doubling down on its commitment to serving its hometown. Timed to National Hot Dog Day (July 15), the announcement brings the iconic Chicago-born brand to one of the city’s most beloved neighborhoods, where baseball fans and residents alike have long requested a Portillo’s restaurant. “There’s no better day to announce a new Portillo’s location than National Hot Dog...

Advancing a pipeline of in vivo CAR-T product candidates for oncology and immunology applications differentiated by CD7-targeted mRNA/LNP delivery approach Lead candidate TPST-4003 combines proprietary CD7-targeted mRNA/LNP delivery with a clinically validated dual-targeting CD19/BCMA CAR construct to support broad B-cell lineage reset across multiple indications First investigator-initiated trial expected to enroll approximately 10 patients with nervous system autoimmune diseases, including MG and MS, with first patient dosing anticipated in the fourth quarter of 2026 and initial clinical data expected in the first half of 2027BRISBANE, Calif., July 15, 2026 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced chimeric antigen receptor...

GREENWICH, Conn., July 15, 2026 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO), the world’s largest pure-play contract logistics provider, today announced it will host its 2026 Investor Day on Monday, November 16, at the New York Stock Exchange. The in-person event will begin at 9:00 a.m. Eastern Time and will also be webcast live. The event will feature presentations from GXO CEO Patrick Kelleher, CFO Mark Suchinski and members of the executive leadership team on the company’s long-term strategy, financial framework and value creation opportunities. The webcast and presentation materials will be available on the Company’s Investor Relations website at investors.gxo.com. A replay will be available following the event. About GXO GXO Logistics, Inc. (NYSE: GXO) is the world’s largest pure-play contract logistics provider and...

Provides Progress on Feasibility Study and Updated PEA; Announces Q2-2026 Financial Release Date MONTREAL, July 15, 2026 (GLOBE NEWSWIRE) — Aya Gold & Silver Inc. (TSX: AYA; NASDAQ: AYA) (“Aya” or the “Company”) is pleased to provide an update on workstreams supporting the Feasibility Study (“FS”) for the Boumadine Project (“Boumadine”), which commenced in early 2026 and is progressing as planned. The Company also continues to advance work on an updated Preliminary Economic Assessment (the “Updated PEA”) for the Boumadine Project, following the completion of a Preliminary Economic Assessment, the results of which were announced on November 4, 2025  (the “2025 PEA”), and the associated NI 43-101 technical report filed on December 18, 2025. “We are very pleased with the progress being made across all...

HOUSTON, July 15, 2026 (GLOBE NEWSWIRE) — Talen Energy Corporation (“Talen”) (NASDAQ: TLN) plans to release its second quarter 2026 financial results on Wednesday, August 5, 2026, after market close. Chief Executive Officer Mac McFarland, President Terry Nutt, and Chief Financial Officer Cole Muller will discuss the financial and operating results during an earnings call at 4:30 p.m. ET (3:30 p.m. CT) on August 5, 2026. To listen to the earnings call, please register in advance for the webcast here. For participants joining the call via phone, please register here prior to the start time to receive dial-in information. For those unable to participate in the live event, a digital replay will be archived for approximately one year and available on the Events page of Talen’s Investor Relations website linked here. About...

The study points to soluble TNF as a key biological link between head injury and Alzheimer’s disease and shows that selectively neutralizing it with XPro1595 prevents the injury-induced rise in amyloid pathology while improving early cognitive and pain-related outcomes. Boca Raton, FL, July 15, 2026 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB), a late-stage inflammation and immunology company, today announced the publication of a new peer-reviewed preclinical study in the Journal of Neurotrauma examining how traumatic brain injury (TBI) drives the biological changes that link head injury to Alzheimer’s disease (AD). The Department of Defense–funded study; entitled: “Inhibition of Soluble TNF Mitigates Traumatic Brain Injury as a Risk Factor for the Development of Amyloidogenic Proteins and Functional Deficits in 3xTg-AD Mice”;...

First Operational Prototype Completes Initial Field-Readiness Testing — WrapShield’s Non-Lethal Response Layer Now Spans Three Coordinated Delivery Mechanisms         MIAMI, July 15, 2026 (GLOBE NEWSWIRE) — WRAP Technologies, Inc. (NASDAQ: WRAP) (“WRAP” or the “Company”), developer of the WrapShield™ Autonomous Public Safety Platform, today announced the completion of the first operational prototype of Wraptor MX™, the Company’s multi-shot non-lethal restraint platform. WrapShield’s Non-Lethal Response™ layer — previously served by a single instrument, the BolaWrap® 150 — now has a newly unveiled operational component. Together with the DFR-X drone-deployed restraint system, WrapShield is designed to bring together three dedicated non-lethal delivery mechanisms — handheld, multi-shot, and drone-deployed —...